Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In general, the majority of potential adverse effects are predominantly associated with inappropriate administration methods that may cause systemic exposure and/or toxicity associated with overexposure to an anesthetic. Regardless, allergic reactions may also occur – although only rarely.
Science-backed ERA derivation by certified toxicologists with ex-agency experts -
Levobupivacaine
Drug Overview
What is Levobupivacaine?
Masuu Global provides end-to-end Environmental Risk Assessment (ERA) support for pharmaceutical and healthcare products, covering Phase I environmental exposure assessment, Phase II environmental fate and effects assessment, data-gap analysis, testing strategy, laboratory coordination and final regulatory-ready reporting.
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →ERA Phase I Evaluation, ERA Phase II Evaluation, Consortium Testing Support (OECD Ecotoxicology Study)
Regulatory Framework
Assessment Methodology
Masuu Global follows a science-based, tiered and risk-based ERA methodology, aligned with applicable international regulatory requirements. For human medicinal products, our approach is primarily guided by the EMA Guideline EMEA/CHMP/SWP/4447/00 Rev. 1, effective 1 September 2024, together with relevant OECD Test Guidelines and regional regulatory requirements.
EMA — Environmental Risk Assessment
Assessment of potential environmental exposure associated with the use, manufacture and disposal of medicinal products, with a structured approach to determine whether further environmental assessment is required.
Phase I — Environmental Exposure Assessment
Initial screening to determine potential environmental exposure, covering PEC calculation, physicochemical properties, usage and dosage data, environmental entry pathways, and persistence and fate considerations.
Phase II — Environmental Fate & Effects Assessment
Where Phase I indicates further assessment is required, Phase II provides detailed evaluation of environmental fate, persistence and ecological effects — including biodegradation, bioaccumulation, aquatic toxicity, PNEC derivation and PEC/PNEC risk characterisation.
OECD & International Testing Principles
Where laboratory studies are required, testing strategies are designed with consideration of relevant OECD Test Guidelines, GLP expectations and applicable regulatory requirements.
Risk-Based Environmental Assessment
Integration of physicochemical data, environmental fate information, ecotoxicological data, existing literature, published studies, regulatory databases, usage data, and environmental monitoring data.
Weight-of-Evidence (WoE) Approach
A scientifically justified WoE approach integrates existing data and avoids unnecessary testing wherever scientifically and regulatorily justified.
ERA Assessment Pathway
Phase I → Phase II → Risk Characterization
Each phase builds on the prior tier — screening first, escalating only when the evidence demands it.
Environmental Exposure Assessment
Initial screening to determine whether the substance requires progression to Phase II.
- Product and substance information review
- Indication, dose and usage assessment
- PEC calculation and environmental exposure estimation
- Physicochemical property review
- Initial environmental risk screening
- Determination of Phase II requirement
Environmental Fate & Effects
Detailed evaluation when Phase I triggers further assessment.
- Biodegradation, hydrolysis & photolysis
- Adsorption/desorption behaviour
- Bioaccumulation potential
- Algal, Daphnia and fish toxicity
- Chronic ecotoxicity, where required
- PEC/PNEC risk characterisation
Laboratory Coordination & Study Execution
When regulatory testing is mandatory, Masuu coordinates with qualified GLP/appropriate testing laboratories and specialized scientific partners — giving clients a single point of contact across the full testing lifecycle.
Final ERA Report — Contents
- Executive summary
- Substance & product information
- Environmental exposure assessment
- Phase I evaluation
- Phase II assessment (where applicable)
- Environmental fate assessment
- Ecotoxicological assessment
- PEC/PNEC calculations
- Risk characterisation
- Data gap evaluation
- Testing rationale
- Risk mitigation considerations
- References and supporting scientific evidence
How We Work
Report Preparation Process
Every ERA follows a structured, tiered workflow designed to deliver scientifically defensible and regulator-ready assessments.
Comprehensive Data Collection
Product, substance, usage, physicochemical, toxicological, environmental and regulatory information collected and reviewed.
Phase I Environmental Screening
Environmental exposure assessment and determination of whether the assessment can conclude at Phase I or requires progression.
Phase II Evaluation
Detailed environmental fate and ecotoxicological assessment when Phase II is triggered.
Data Gap & Testing Strategy
Missing information identified and available alternatives evaluated before recommending additional testing.
Consortium Testing Support
Where testing is mandatory, Masuu coordinates with qualified testing partners through its Consortium Model.
Scientific & Regulatory Review
Integration and critical review of generated and existing data by experienced scientific and regulatory experts.
Final ERA Delivery
Comprehensive ERA report with transparent methodology, scientific rationale, calculations, conclusions and regulatory recommendations.
Ex-Agency Advantage
Why Masuu Global?
Our experienced regulatory and scientific experts bring a practical regulatory perspective — helping clients understand not only what data are required, but why they are required and how regulators may evaluate them.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 7,000+ molecules.